Search Results

You are looking at 11 - 20 of 886 items for :

  • "risk factor" x
  • Refine by Access: All x
Clear All
Full access

A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora

Leila Family, Yanli Li, Lie Hong Chen, John H. Page, Zandra K. Klippel, and Chun Chao

of a given patient's FN risk depends on knowledge of key FN risk factors. The performance of currently available FN prediction models in the literature indicated room for improvement in clinical FN risk prediction. 18 , 19 Thus, the objective of this

Full access

Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, and Dwight H. Owen

summarized and compared between those with and without SREs using the Fisher exact test for the categorical risk factors and the Kruskal-Wallis test for the continuous variables. All statistical analyses were performed using SAS, version 9.4 (SAS Institute

Full access

Increasing Incidence of Intrahepatic Cholangiocarcinoma and its Relationship to Chronic Viral Hepatitis

Kwang-Yu Chang, Jang-Yang Chang, and Yun Yen

– 281 . 9 Su CH Shyr YM Lui WY P’Eng FK . Hepatolithiasis associated with cholangiocarcinoma . Br J Surg 1997 ; 84 : 969 – 973 . 10 Ahrens W Timmer A Vyberg M . Risk factors for extrahepatic biliary tract carcinoma in men

Full access

Epidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 2010

Mikkael A. Sekeres

be an overestimate, a rate of 60,000 people likely underestimates the impact of the disease. Risk Factors for Developing MDS The greatest risk factor for developing MDS is advanced age, with yearly incidence rates increasing 10-fold for

Full access

NCCN Task Force Report: Bone Health and Cancer Care

Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak

critical issue for all cancer patients, regardless of other risk factors, and should be incorporated into comprehensive cancer care. An American Society of Clinical Oncology (ASCO) Task Force statement on bone health in women with breast cancer noted, “Many

Full access

Refusal of Recommended Chemotherapy for Ovarian Cancer: Risk Factors and Outcomes; a National Cancer Data Base Study

Sumer K. Wallace, Jeff F. Lin, William A. Cliby, Gary S. Leiserowitz, Ana I. Tergas, and Robert E. Bristow

) view/print certificate. Release date: May 12, 2016; Expiration date: May 12, 2017 Learning Objectives Upon completion of this activity, participants will be able to: Identify risk factors associated with refusal of recommended chemotherapy

Full access

Update on Guidelines for the Prevention of Cancer-Associated Thrombosis

Amro Elshoury, Jordan K. Schaefer, Ming Y. Lim, Deidre P. Skalla, and Michael B. Streiff

conditions is still referred to as Trousseau syndrome. Patients with cancer constitute 15% to 20% of the patients diagnosed with venous thromboembolism (VTE). 3 Depending on the type of tumor, cancer therapy, and presence of other risk factors, 1% to 25% of

Full access

Local Recurrence and Disease-Free Survival After Transanal Total Mesorectal Excision: Results From the International TaTME Registry

Sapho X. Roodbeen, Marta Penna, Susan van Dieren, Brendan Moran, Paris Tekkis, Pieter J. Tanis, Roel Hompes, and on behalf of the International TaTME Registry Collaborative

of LR (whether unifocal or multicentric), independent risk factors for LR, and 2-year DFS and OS rates. DFS was defined as patients who were alive without evidence of local or distant recurrence. OS was defined as those who were alive with or

Full access

Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors

Mohammad Abu Zaid, Paul C. Dinh Jr, Patrick O. Monahan, Chunkit Fung, Omar El-Charif, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra Althouse, Shirin Ardeshir-Rouhani-Fard, Howard D. Sesso, Robert Huddart, Taisei Mushiroda, Michiaki Kubo, M. Eileen Dolan, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis, and for the Platinum Study Group

Platinum Study ( P =.30), and other clinical and sociodemographic characteristics ( supplemental eTable 1 , available with this article at ). Data on the prevalence of metabolic syndrome and its risk factors in this cohort have been previously

Full access

Risk Factors for the Assessment of Patients with Pulmonary Embolism

John Fanikos and Samuel Z. Goldhaber

: a 25 year population based study . Arch Intern Med 1998 ; 15 : 585 – 593 . 5. Heit JA Silverstein MD Mohr DN . Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study . Arch Intern Med